---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-205522"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:22:10.135890+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P

## Summary
- ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).
- Average fold increase 145.3x over baseline; median 44.3x; 80% of patients above 9.5x threshold correlated with clinical activity in Phase 1.
- 85% of patients had combined CD4+CD8 T cell response vs 75% in Phase 1; 67.4% responded to all 7 mKRAS antigens vs 50%.
- IDMC recommended continue without modifications after interim safety/efficacy review; company remains blinded to clinical outcomes.
- Final disease-free survival analysis anticipated in Q4 2025; Phase 2 includes both MRD+ and MRD- patients.

## SEC filing metadata
- accession: 0001193125-25-205522
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/0001193125-25-205522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/d38971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-205522
- JSON: https://secwatch.observer/filing/0001193125-25-205522.json
- Plain text: https://secwatch.observer/filing/0001193125-25-205522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.